TrialHepatology (Baltimore, Md.)2021

Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.

Oliver E Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.